Cargando…
Initial Experience of A Heart Failure Disease Management Clinic During the Covid-19 Era
BACKGROUND: The COVID-19 pandemic has necessitated significant alterations in ambulatory heart failure (HF) care, primarily with the introduction of telemedicine. We describe our initial experience caring for patients in the COVID-19 era in the Johns Hopkins Heart Failure Bridge Clinic (JHHFBC), an...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527193/ http://dx.doi.org/10.1016/j.cardfail.2020.09.466 |
_version_ | 1783589005412007936 |
---|---|
author | Cuomo, Kimberly Menzel, Kathryn Hubbard, Abby Riley, Sarah Umapathi, Priya Sauer, Erica Fitts, Falisha Gilotra, Nisha |
author_facet | Cuomo, Kimberly Menzel, Kathryn Hubbard, Abby Riley, Sarah Umapathi, Priya Sauer, Erica Fitts, Falisha Gilotra, Nisha |
author_sort | Cuomo, Kimberly |
collection | PubMed |
description | BACKGROUND: The COVID-19 pandemic has necessitated significant alterations in ambulatory heart failure (HF) care, primarily with the introduction of telemedicine. We describe our initial experience caring for patients in the COVID-19 era in the Johns Hopkins Heart Failure Bridge Clinic (JHHFBC), an ambulatory disease management and diuresis clinic aimed at preventing hospitalizations. METHODS: The JHHFBC sees about 2500 patients per year with 25% of those patients needing intravenous diuretics in the clinic. Starting March 16, 2020, we implemented a COVID-specific workflow incorporating telemedicine, which the clinic had previously not been utilizing. Patient visit outcomes were adjudicated, including change in diuretic dosing, intravenous diuretic administration, and need for hospitalization. RESULTS: From March 16, 2020 to April 24, 2020 we had 116 patients seen 164 times (Figure 1). The average age of patients was 61 ± 14 years, 50% female, and 70% Black. Average left ventricular ejection fraction was 25 ± 21% with 45% nonischemic cardiomyopathy, 14% ischemic cardiomyopathy, 6% amyloid, 35% had heart failure with preserved ejection fraction. The majority of patients were New York Heart Association (NYHA) class II or III (109, 94%). Reasons for clinic referral included an equal frequency of post hospital discharge, worsening HF symptoms and routine follow up. Of the 96 telemedicine visits, 23% resulted in oral diuretic dose adjustment and 6 patients were referred for in-person visits. Of the 68 in-person visits, 34 (50%) resulted in intravenous diuretic administration in clinic, with 8 referrals to the emergency department or for direct admission. There were 2 referrals for cardioversion and 3 referrals to hospice by the clinic. Two of 16 clinic patients that were tested for Covid 19 were positive. CONCLUSION: We found that HF patients could be effectively managed via telemedicine, however a subset still benefit from in-person assessment and access to ambulatory intravenous diuresis to avoid hospitalization. We hope these initial experiences will lend insights to optimization of future outpatient HF care, including the use of telemedicine, even after the current global health emergency. |
format | Online Article Text |
id | pubmed-7527193 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Published by Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75271932020-10-01 Initial Experience of A Heart Failure Disease Management Clinic During the Covid-19 Era Cuomo, Kimberly Menzel, Kathryn Hubbard, Abby Riley, Sarah Umapathi, Priya Sauer, Erica Fitts, Falisha Gilotra, Nisha J Card Fail Enc-004 BACKGROUND: The COVID-19 pandemic has necessitated significant alterations in ambulatory heart failure (HF) care, primarily with the introduction of telemedicine. We describe our initial experience caring for patients in the COVID-19 era in the Johns Hopkins Heart Failure Bridge Clinic (JHHFBC), an ambulatory disease management and diuresis clinic aimed at preventing hospitalizations. METHODS: The JHHFBC sees about 2500 patients per year with 25% of those patients needing intravenous diuretics in the clinic. Starting March 16, 2020, we implemented a COVID-specific workflow incorporating telemedicine, which the clinic had previously not been utilizing. Patient visit outcomes were adjudicated, including change in diuretic dosing, intravenous diuretic administration, and need for hospitalization. RESULTS: From March 16, 2020 to April 24, 2020 we had 116 patients seen 164 times (Figure 1). The average age of patients was 61 ± 14 years, 50% female, and 70% Black. Average left ventricular ejection fraction was 25 ± 21% with 45% nonischemic cardiomyopathy, 14% ischemic cardiomyopathy, 6% amyloid, 35% had heart failure with preserved ejection fraction. The majority of patients were New York Heart Association (NYHA) class II or III (109, 94%). Reasons for clinic referral included an equal frequency of post hospital discharge, worsening HF symptoms and routine follow up. Of the 96 telemedicine visits, 23% resulted in oral diuretic dose adjustment and 6 patients were referred for in-person visits. Of the 68 in-person visits, 34 (50%) resulted in intravenous diuretic administration in clinic, with 8 referrals to the emergency department or for direct admission. There were 2 referrals for cardioversion and 3 referrals to hospice by the clinic. Two of 16 clinic patients that were tested for Covid 19 were positive. CONCLUSION: We found that HF patients could be effectively managed via telemedicine, however a subset still benefit from in-person assessment and access to ambulatory intravenous diuresis to avoid hospitalization. We hope these initial experiences will lend insights to optimization of future outpatient HF care, including the use of telemedicine, even after the current global health emergency. Published by Elsevier Inc. 2020-10 2020-09-30 /pmc/articles/PMC7527193/ http://dx.doi.org/10.1016/j.cardfail.2020.09.466 Text en Copyright © 2020 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Enc-004 Cuomo, Kimberly Menzel, Kathryn Hubbard, Abby Riley, Sarah Umapathi, Priya Sauer, Erica Fitts, Falisha Gilotra, Nisha Initial Experience of A Heart Failure Disease Management Clinic During the Covid-19 Era |
title | Initial Experience of A Heart Failure Disease Management Clinic During the Covid-19 Era |
title_full | Initial Experience of A Heart Failure Disease Management Clinic During the Covid-19 Era |
title_fullStr | Initial Experience of A Heart Failure Disease Management Clinic During the Covid-19 Era |
title_full_unstemmed | Initial Experience of A Heart Failure Disease Management Clinic During the Covid-19 Era |
title_short | Initial Experience of A Heart Failure Disease Management Clinic During the Covid-19 Era |
title_sort | initial experience of a heart failure disease management clinic during the covid-19 era |
topic | Enc-004 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527193/ http://dx.doi.org/10.1016/j.cardfail.2020.09.466 |
work_keys_str_mv | AT cuomokimberly initialexperienceofaheartfailurediseasemanagementclinicduringthecovid19era AT menzelkathryn initialexperienceofaheartfailurediseasemanagementclinicduringthecovid19era AT hubbardabby initialexperienceofaheartfailurediseasemanagementclinicduringthecovid19era AT rileysarah initialexperienceofaheartfailurediseasemanagementclinicduringthecovid19era AT umapathipriya initialexperienceofaheartfailurediseasemanagementclinicduringthecovid19era AT sauererica initialexperienceofaheartfailurediseasemanagementclinicduringthecovid19era AT fittsfalisha initialexperienceofaheartfailurediseasemanagementclinicduringthecovid19era AT gilotranisha initialexperienceofaheartfailurediseasemanagementclinicduringthecovid19era |